F Dx Advisors, Inc. Bristol Myers Squibb CO Transaction History

F Dx Advisors, Inc.

$362 Million
Q2 2024

A detailed history of F Dx Advisors, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, F Dx Advisors, Inc. holds 5,346 shares of BMY stock, worth $276,655. This represents 0.06% of its overall portfolio holdings.

Number of Shares

5,346

Previous 5,493 2.68%

Holding current value

$276,655

Previous $298,000 25.5%

% of portfolio

0.06%

Previous 0.05%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 02, 2024	SELL	$40.25 - $52.99 $5,916 - $7,789	-147 Reduced 2.68%	5,346 $222,000
Q1 2024 May 03, 2024	SELL	$47.98 - $54.4 $247,240 - $280,323	-5,153 Reduced 48.4%	5,493 $298,000
Q4 2023 Feb 12, 2024	BUY	$48.48 - $57.85 $77,034 - $91,923	1,589 Added 17.54%	10,646 $546,000
Q3 2023 Nov 02, 2023	SELL	$57.89 - $64.73 $338,309 - $378,282	-5,844 Reduced 39.22%	9,057 $525,000
Q2 2023 Jul 17, 2023	SELL	$63.71 - $70.74 $187,052 - $207,692	-2,936 Reduced 16.46%	14,901 $952,000
Q4 2022 Feb 09, 2023	SELL	$68.48 - $81.09 $145,177 - $171,910	-2,120 Reduced 10.62%	17,837 $1.28 Million
Q3 2022 Nov 10, 2022	BUY	$0.13 - $76.84 $45 - $26,817	349 Added 1.78%	19,957 $1.42 Million
Q2 2022 Aug 03, 2022	SELL	$72.62 - $79.98 $236,232 - $260,174	-3,253 Reduced 14.23%	19,608 $1.51 Million
Q1 2022 May 03, 2022	BUY	$61.48 - $73.72 $304,817 - $365,503	4,958 Added 27.69%	22,861 $1.67 Million
Q4 2021 Feb 01, 2022	SELL	$53.63 - $62.52 $249,433 - $290,780	-4,651 Reduced 20.62%	17,903 $1.12 Million
Q3 2021 Oct 08, 2021	SELL	$59.17 - $69.31 $458,981 - $537,637	-7,757 Reduced 25.59%	22,554 $1.34 Million
Q2 2021 Aug 05, 2021	BUY	$61.91 - $67.42 $532,921 - $580,351	8,608 Added 39.66%	30,311 $2.03 Million
Q1 2021 Apr 14, 2021	BUY	$59.34 - $66.74 $1.21 Million - $1.36 Million	20,333 Added 1484.16%	21,703 $1.37 Million
Q1 2021 Apr 13, 2021	SELL	$59.34 - $66.74 $1.97 Million - $2.21 Million	-33,176 Reduced 96.03%	1,370 $86,000
Q4 2020 Feb 08, 2021	BUY	$57.74 - $65.43 $113,401 - $128,504	1,964 Added 6.03%	34,546 $2.14 Million
Q3 2020 Nov 12, 2020	SELL	$57.43 - $63.64 $340,732 - $377,576	-5,933 Reduced 15.4%	32,582 $1.96 Million
Q2 2020 Jul 22, 2020	BUY	$54.82 - $64.09 $362,634 - $423,955	6,615 Added 20.74%	38,515 $2.27 Million
Q1 2020 May 22, 2020	BUY	$46.4 - $67.43 $643,011 - $934,444	13,858 Added 76.81%	31,900 $1.78 Million
Q1 2020 May 13, 2020	SELL	$46.4 - $67.43 $868,654 - $1.26 Million	-18,721 Reduced 50.92%	18,042 $210,000
Q4 2019 Feb 12, 2020	BUY	$49.21 - $64.19 $202,154 - $263,692	4,108 Added 12.58%	36,763 $2.36 Million
Q3 2019 Nov 07, 2019	BUY	$42.77 - $50.71 $312,648 - $370,690	7,310 Added 28.84%	32,655 $1.66 Million
Q2 2019 Jul 19, 2019	BUY	$44.62 - $49.34 $80,672 - $89,206	1,808 Added 7.68%	25,345 $1.15 Million
Q1 2019 May 14, 2019	BUY	$45.12 - $53.8 $247,257 - $294,824	5,480 Added 30.35%	23,537 $1.12 Million
Q4 2018 Apr 29, 2019	SELL	$48.76 - $63.23 $2.9 Million - $3.76 Million	-59,513 Reduced 76.72%	18,057 $939,000
Q4 2018 Feb 07, 2019	BUY	$48.76 - $63.23 $2.09 Million - $2.71 Million	42,911 Added 123.81%	77,570 $4.03 Million
Q3 2018 Nov 13, 2018	BUY	$55.19 - $62.25 $1.49 Million - $1.68 Million	26,984 Added 351.58%	34,659 $2.15 Million
Q2 2018 Aug 08, 2018	SELL	$50.53 - $62.98 $1.23 Million - $1.53 Million	-24,330 Reduced 76.02%	7,675 $425,000
Q1 2018 May 02, 2018	BUY	$59.92 - $68.98 $221,404 - $254,881	3,695 Added 13.05%	32,005 $2.02 Million
Q4 2017 Feb 09, 2018	SELL	$59.94 - $65.35 $459,140 - $500,580	-7,660 Reduced 21.3%	28,310 $1.74 Million
Q3 2017 Nov 03, 2017	BUY	$55.23 - $63.74 $62,520 - $72,153	1,132 Added 3.25%	35,970 $2.29 Million
Q2 2017 Aug 11, 2017	BUY	N/A	34,838	34,838 $1.94 Million

Others Institutions Holding BMY

# of Institutions

2,402

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $110B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of F Dx Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on F Dx Advisors, Inc. with notifications on news.

Account